8NE:FRA
Lisata Therapeutics, Inc.
€ ०.८२
arrow_downward
-०.६१%(-०.००५०) 1D
अक्टोबर १३, २२:००:०० GMT+२ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 8NE...
Open
€ ०.८२
High
€ ०.८२
Low
€ ०.८२
Mkt. cap
१.१७ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ ४.३४
52-wk low
€ ०.७४
No. of employees
२१
Open
€ ०.८२
High
€ ०.८२
Low
€ ०.८२
Mkt. cap
१.१७ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ ४.३४
52-wk low
€ ०.७४
No. of employees
२१
News stories
From web sources and news partners
GlobeNewswire
·
१६ मिनेट पहिले
Nasdaq Confirmed AGM Group Holdings Inc. Complies with The Nasdaq Listing Rules
The Chronicle-Journal
·
९ मिनेट पहिले
AZZ (NYSE:AZZ) Beats Expectations in Strong Q3 CY2026, Full-Year Sales Guidance is Optimistic
24/7 Wall St.
·
२३ मिनेट पहिले
S&P 500 Closes Flat at 7,804 While Selling Stays Concentrated
Seeking Alpha
·
२२ मिनेट पहिले
Three things to look out for on Wednesday
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees२१
Founded१९८०
HeadquartersBasking Ridge, न्यु जर्सी, संयुक्त राज्य अमेरिका
Sector-
Websitelisata.com